IBD 50 stock Grifols (GRFS) has relied on global expansion to escape economic troubles in its home country of Spain. The company became among the world’s biggest makers of plasma products two years ago when it purchased North Carolina-based Talecris Biotherapeutics for $3.4 billion. Now, more than 90% of Grifols’ income comes from outside of Spain, which was hit especially hard by the global financial crisis.